Teva’s bid to combine with the generic-drug business of Allergan would vault the Israeli company into the top ranks of global drug makers and further a remodeling of the industry by a few players that were relatively unknown just a few years ago.
WSJ.com: Middle East News, Wall Street Journal: World: Middle East
Sun, 07/26/2015 - 6:22pm
Teva’s bid to combine with the generic-drug business of Allergan would vault the Israeli company into the top ranks of global drug makers and further a remodeling of the industry by a few players that were relatively unknown just a few years ago.